Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT

J Int Med Res. 2007 Jul-Aug;35(4):547-53. doi: 10.1177/147323000703500415.

Abstract

This study aimed to detect metastases in patients with stage III or IV cutaneous melanoma by (18)F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT). Thirty-nine patients with clinically evident stage III or IV melanoma underwent whole-body FDG-PET/CT scans for metastatic disease and these results were compared with those of biopsy. Scans for 38 of the patients were evaluated; one patient's scan could not be evaluated. There were 11 true-positive, two false-positive, 24 true-negative and one false-negative scans for the detection of melanoma metastases, with sensitivity 91%, specificity 92%, accuracy 92%, and positive and negative predictive values 84% and 96%, respectively. False-positive FDG-PET/CT scans were due to sarcoidosis in the lung and infected cyst in the liver. It is concluded that FDG-PET/CT scanning has high sensitivity and specificity for detecting stage III or IV metastatic melanoma.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Diagnostic Errors
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Melanoma / diagnostic imaging*
  • Melanoma / secondary*
  • Middle Aged
  • Neoplasm Metastasis / diagnostic imaging*
  • Neoplasm Staging
  • Radiopharmaceuticals*
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Skin Neoplasms / diagnostic imaging*
  • Skin Neoplasms / pathology*
  • Tomography, Emission-Computed*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18